JP2011523351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523351A5 JP2011523351A5 JP2011506301A JP2011506301A JP2011523351A5 JP 2011523351 A5 JP2011523351 A5 JP 2011523351A5 JP 2011506301 A JP2011506301 A JP 2011506301A JP 2011506301 A JP2011506301 A JP 2011506301A JP 2011523351 A5 JP2011523351 A5 JP 2011523351A5
- Authority
- JP
- Japan
- Prior art keywords
- variable domain
- antibody
- domain sequence
- fcrn
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 28
- 102000004965 antibodies Human genes 0.000 claims 28
- 102100014838 FCGRT Human genes 0.000 claims 15
- 101710003435 FCGRT Proteins 0.000 claims 15
- 102000018358 Immunoglobulins Human genes 0.000 claims 7
- 108060003951 Immunoglobulins Proteins 0.000 claims 7
- 102000004851 Immunoglobulin G Human genes 0.000 claims 4
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000000051 modifying Effects 0.000 claims 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 206010028417 Myasthenia gravis Diseases 0.000 claims 2
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000036963 noncompetitive Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 230000036499 Half live Effects 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000007313 Kawasaki disease Diseases 0.000 claims 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 1
- 108010035649 Natalizumab Proteins 0.000 claims 1
- 208000004235 Neutropenia Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 208000003782 Raynaud Disease Diseases 0.000 claims 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims 1
- 208000006045 Spondylarthropathy Diseases 0.000 claims 1
- 206010052775 Spondyloarthropathy Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
Claims (15)
- 重鎖(HC)免疫グロブリン可変ドメイン配列及び軽鎖(LC)免疫グロブリン可変ドメイン配列を含む単離抗体であって、
重鎖及び軽鎖免疫グロブリン可変ドメイン配列が、ヒトFcRnに結合する抗原結合部位を形成し;以下の特徴の1以上を有する抗体:
(a)ヒトCDR又はヒトフレームワーク領域;
(b)LC免疫グロブリン可変ドメイン配列が、M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、またはM0090−F11、のLC可変ドメインのCDRと少なくとも85%同一である1つ以上のCDRを含む;
(c)HC免疫グロブリン可変ドメイン配列が、M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、またはM0090−F11、のHC可変ドメインのCDRと少なくとも85%同一である1つ以上のCDRを含む;
(d)LC免疫グロブリン可変ドメイン配列が、M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、またはM0090−F11のLC可変ドメインと少なくとも85%同一である;
(e)HC免疫グロブリン可変ドメイン配列が、M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、またはM0090−F11のHC可変ドメインと少なくとも85%同一である;及び
(f)抗体が、M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、またはM0090−F11の結合するエピトープと重複するエピトープに結合する。
- (a)M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、およびM0090−F11からなる群から選択される;
(b)M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、またはM0090−F11のCDRを有する;または
(c)M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、およびM0090−F11からなる群から選ばれる抗体と少なくとも85%同一である、単離抗体。
- (a)HC可変ドメイン配列がM0161−B04の可変ドメインの配列を有し、LC可変ドメインの配列がM0161−B04の可変ドメインの配列を有する;
(b)HC可変ドメイン配列がM0171−A01の可変ドメインの配列を有し、LC可変ドメインの配列がM0171−A01の可変ドメインの配列を有する;
(c)HC可変ドメイン配列がDX2500の可変ドメインの配列を有し、LC可変ドメインの配列がM0DX2500の可変ドメインの配列を有する;
(d)HC可変ドメイン配列がMM0171−A03の可変ドメインの配列を有し、LC可変ドメインの配列がM0171−A03の可変ドメインの配列を有する;
(e)HC可変ドメイン配列がMM0159−A07の可変ドメインの配列を有し、LC可変ドメインの配列がM0159−A07の可変ドメインの配列を有する;または
(f)HC可変ドメイン配列がM0090−F11の可変ドメインの配列を有し、LC可変ドメインの配列がM0090−F11の可変ドメインの配列を有する、請求項1の抗体。
- M0161−B04、M0171−A01、DX2500、M0171−A03、M0159−A07、またはM0090−F11と結合されるFcRnエピトープと結合する請求項1の抗体。
- ヒトFcRnに結合する単離抗体またはその断片であって、前記抗体がヒトFcRnの重鎖またはその断片に対して産生され、前記抗体がIgGのヒトFcRnへの結合の非競合的阻害剤として機能し、前記抗体がβ2−マイクログロブリンに結合しない、単離抗体又はその断片。
- 請求項1から5のいずれか一項に記載の抗体と、薬学的に許容できる担体とを含む医薬組成物。
- 試料中のFcRnを検出する方法であって、前記試料を請求項1から5のいずれか一項に記載の抗体と接触させることと、前記抗体と、存在する場合FcRnとの間の相互作用を検出することとを含む方法。
- FcRn活性を調節する方法であって、請求項1から5のいずれか一項に記載の抗体とFcRnとを接触させ、それによりFcRn活性を調節することを含む方法。
- ヒト対象においてFcRn活性の調節に使用するための請求項1から5のいずれか一項に記載の抗体。
- 自己免疫障害の治療及び/又は自己免疫障害の症状の調節に使用するための請求項1から5のいずれか一項に記載の抗体。
- 自己免疫障害が、関節リウマチ(RA)、全身性エリテマトーデス(SLE)、重症筋無力症(MG)、グレーブス病、特発性血小板減少性紫斑病(ITP)、ギランバレー症候群、自己免疫性心筋炎、膜型糸球体腎炎、真性糖尿病、I型又はII型糖尿病、多発性硬化症、レイノー症候群、自己免疫性甲状腺炎、胃炎、セリアック病、白斑、肝炎、原発性胆汁性肝硬変、炎症性腸疾患、脊椎関節症、実験的自己免疫性脳脊髄炎、免疫性好中球減少症、若年発症糖尿病、サイトカイン仲介性遅延型過敏症に関連する免疫反応、典型的には結核で見られるTリンパ球、サルコイドーシス、多発性筋炎、多発性動脈炎、皮膚血管炎、天疱瘡、類天疱瘡、グッドパスチャー症候群、川崎病、全身性硬化症、抗リン脂質症候群、及びシェーグレン症候群から成る群から選択される、請求項10の抗体。
- 循環IgGの半減期/量を調節するのに使用する請求項1から5のいずれかに記載の抗体。
- 個体中の不所望の抗体濃度を低下させるのに使用する請求項1から5のいずれかに記載の抗体またはその断片。
- 不所望の抗体がナタリズマブである請求項13の抗体またはその断片。
- ヒトFcRnに結合する抗体またはその断片であって、ヒトFcRnの重鎖またはその断片に対して産生され、前記抗体がIgGのヒトFcRnへの結合の非競合的阻害剤として機能し、前記抗体がβ2−マイクログロブリンに結合せず、個体におけるIgGのFcRnへの結合を減少させるために使用する、抗体又はその断片。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4815208P | 2008-04-25 | 2008-04-25 | |
US61/048,152 | 2008-04-25 | ||
US4850008P | 2008-04-28 | 2008-04-28 | |
US61/048,500 | 2008-04-28 | ||
PCT/US2009/002536 WO2009131702A2 (en) | 2008-04-25 | 2009-04-24 | Antibodies against fcrn and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015027638A Division JP5989159B2 (ja) | 2008-04-25 | 2015-02-16 | FcRnに対する抗体及びその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011523351A JP2011523351A (ja) | 2011-08-11 |
JP2011523351A5 true JP2011523351A5 (ja) | 2012-06-07 |
JP6106854B2 JP6106854B2 (ja) | 2017-04-05 |
Family
ID=41203902
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011506301A Active JP6106854B2 (ja) | 2008-04-25 | 2009-04-24 | FcRnに対する抗体及びその使用 |
JP2015027638A Active JP5989159B2 (ja) | 2008-04-25 | 2015-02-16 | FcRnに対する抗体及びその使用 |
JP2016155218A Active JP6499132B2 (ja) | 2008-04-25 | 2016-08-08 | FcRnに対する抗体及びその使用 |
JP2019046955A Pending JP2019162105A (ja) | 2008-04-25 | 2019-03-14 | FcRnに対する抗体及びその使用 |
JP2022075914A Pending JP2022115960A (ja) | 2008-04-25 | 2022-05-02 | FcRnに対する抗体及びその使用 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015027638A Active JP5989159B2 (ja) | 2008-04-25 | 2015-02-16 | FcRnに対する抗体及びその使用 |
JP2016155218A Active JP6499132B2 (ja) | 2008-04-25 | 2016-08-08 | FcRnに対する抗体及びその使用 |
JP2019046955A Pending JP2019162105A (ja) | 2008-04-25 | 2019-03-14 | FcRnに対する抗体及びその使用 |
JP2022075914A Pending JP2022115960A (ja) | 2008-04-25 | 2022-05-02 | FcRnに対する抗体及びその使用 |
Country Status (17)
Country | Link |
---|---|
US (10) | US8273351B2 (ja) |
EP (3) | EP3670538A1 (ja) |
JP (5) | JP6106854B2 (ja) |
KR (4) | KR102072896B1 (ja) |
CN (3) | CN104479017A (ja) |
AU (1) | AU2009238605B2 (ja) |
BR (2) | BR122021026834B1 (ja) |
CA (2) | CA2722082C (ja) |
ES (1) | ES2650804T3 (ja) |
HK (2) | HK1160868A1 (ja) |
IL (2) | IL208846A (ja) |
MX (1) | MX2010011679A (ja) |
NZ (1) | NZ589451A (ja) |
SG (3) | SG10201804513WA (ja) |
TW (3) | TWI547287B (ja) |
WO (1) | WO2009131702A2 (ja) |
ZA (1) | ZA201007873B (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122021026834B1 (pt) * | 2008-04-25 | 2022-11-08 | Takeda Pharmaceutical Company Limited | Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
AU2012262007B2 (en) | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
EP3778889A1 (en) * | 2011-09-30 | 2021-02-17 | Chugai Seiyaku Kabushiki Kaisha | Ion concentration-dependent binding molecule library |
CA2857159C (en) | 2011-11-30 | 2024-05-07 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
SG11201405137QA (en) * | 2012-02-24 | 2014-12-30 | Chugai Pharmaceutical Co Ltd | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB |
CA2871468C (en) | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
LT2935326T (lt) * | 2012-12-21 | 2020-12-10 | Biogen Ma Inc. | Žmogaus antikūnai prieš tau baltymą |
ZA201506407B (en) * | 2013-03-15 | 2018-11-28 | Affibody Ab | New polypeptides |
CN105209482B (zh) * | 2013-03-15 | 2022-04-29 | 阿菲博迪公司 | 新的多肽 |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
US20160075766A1 (en) * | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
CN105848671B (zh) * | 2013-08-28 | 2019-12-13 | 艾伯维施特姆森特克斯有限责任公司 | 位点特异性抗体缀合方法和组合物 |
GB201320066D0 (en) * | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
PT3087095T (pt) * | 2013-12-24 | 2019-10-09 | Argenx Bvba | Antagonistas de fcrn e métodos de utilização |
US20170045528A1 (en) * | 2014-04-25 | 2017-02-16 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating subjects with immune-mediated diseases |
US10336825B2 (en) | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
CA3095295C (en) | 2014-04-30 | 2023-01-10 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
CA2914595C (en) * | 2014-05-19 | 2022-12-13 | F. Hoffmann-La Roche Ag | Method for producing antibodies using ovine b-cells and uses thereof |
RU2725442C2 (ru) | 2014-09-17 | 2020-07-02 | Аффибоди Аб | Новые полипептиды |
NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
HUE063778T2 (hu) * | 2015-01-30 | 2024-01-28 | Momenta Pharmaceuticals Inc | FcRn ellenanyagok és eljárások alkalmazásukra |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
EP3294335B1 (en) * | 2015-05-12 | 2023-07-05 | Syntimmune Inc. | Humanized affinity matured anti-fcrn antibodies |
GB201508180D0 (en) * | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
WO2017035185A1 (en) | 2015-08-24 | 2017-03-02 | University Of Cincinnati | Methods and compositions for the detection of fc receptor binding activity of antibodies |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
IL302288A (en) | 2016-07-29 | 2023-06-01 | Momenta Pharmaceuticals Inc | FCRN antibodies and methods of using them |
CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
US11041014B2 (en) | 2016-10-28 | 2021-06-22 | S & K Biopharma, Inc. | Lactoferrin/albumin fusion protein and production method therefor |
GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
KR20200018643A (ko) * | 2017-06-15 | 2020-02-19 | 유씨비 바이오파마 에스알엘 | 면역 혈소판감소증의 치료 방법 |
US11773168B2 (en) * | 2017-12-13 | 2023-10-03 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
AU2019283673B2 (en) | 2018-06-08 | 2023-12-07 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
WO2020018910A1 (en) * | 2018-07-20 | 2020-01-23 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
US20220144941A1 (en) | 2018-10-16 | 2022-05-12 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
MX2021005048A (es) * | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
JP2022535908A (ja) | 2019-06-07 | 2022-08-10 | アルジェニクス ビーブイ | 皮下投与に好適なFcRnインヒビターの医薬製剤 |
CN114630678A (zh) * | 2019-08-01 | 2022-06-14 | 詹森生物科技公司 | FcRn抗体及其使用方法 |
WO2021160116A1 (zh) * | 2020-02-10 | 2021-08-19 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
KR102507515B1 (ko) * | 2020-08-26 | 2023-03-08 | 이화여자대학교 산학협력단 | 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리 |
CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
US11926669B2 (en) | 2022-05-30 | 2024-03-12 | Hanall Biopharma Co., Ltd. | Anti-FcRn antibody or antigen binding fragment thereof with improved stability |
CN115645537A (zh) * | 2022-10-25 | 2023-01-31 | 成都臻拓医药科技有限公司 | FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途 |
CN116047054A (zh) * | 2023-03-08 | 2023-05-02 | 江西赛基生物技术有限公司 | 用于检测血小板抗体的试剂盒及其制备方法和使用方法 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
DE2901218A1 (de) | 1979-01-13 | 1980-07-17 | Byk Gulden Lomberg Chem Fab | Ung von theophyllin |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE81724T1 (de) | 1987-11-09 | 1992-11-15 | Becton Dickinson Co | Verfahren zur analyse haematopoietischer zellen in einer probe. |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5030002A (en) | 1989-08-11 | 1991-07-09 | Becton, Dickinson And Company | Method and apparatus for sorting particles with a moving catcher tube |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
IE76732B1 (en) | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
US5179107A (en) | 1990-09-07 | 1993-01-12 | Schering Corporation | Antiviral quinolinone compounds |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
DE69326967T2 (de) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phasenmodulationsenergieübertragungsfluoroimmunassay |
SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1997034631A1 (en) * | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
PT971946E (pt) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US6960178B2 (en) | 2000-02-02 | 2005-11-01 | Xepmed, Inc. | Apparatus for enhanced plasmapheresis and methods thereof |
US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
EP2093286B1 (en) | 2001-10-01 | 2013-02-27 | Dyax Corporation | Multi-chain eukaryotic display vectors and uses thereof |
WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
US20050079169A1 (en) | 2003-08-08 | 2005-04-14 | Balthasar Joseph P. | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
JP2008538919A (ja) | 2005-04-29 | 2008-11-13 | ザ ジャクソン ラボラトリー | FcRn抗体およびその使用 |
US20090092507A1 (en) * | 2005-08-05 | 2009-04-09 | Ramirez Jr Emilio A | Fluid pump systems |
EP1986690A4 (en) * | 2006-01-25 | 2009-05-13 | Univ New York State Res Found | ANTIBODIES AGAINST FCRN FOR THE TREATMENT OF AUTO / ALLO IMMUNOIDES |
US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
KR102467302B1 (ko) | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
BR122021026834B1 (pt) | 2008-04-25 | 2022-11-08 | Takeda Pharmaceutical Company Limited | Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn |
AU2012262007B2 (en) * | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
EA202091410A1 (ru) * | 2017-12-08 | 2021-01-13 | Ардженкс Бвба | Применение антагонистов fcrn для лечения генерализованной миастении гравис |
AU2019283673B2 (en) * | 2018-06-08 | 2023-12-07 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
JP2022532229A (ja) * | 2019-05-17 | 2022-07-13 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 天疱瘡及び類天疱瘡疾患の治療における抗FcRn抗体の使用 |
-
2009
- 2009-04-24 BR BR122021026834-7A patent/BR122021026834B1/pt active IP Right Grant
- 2009-04-24 WO PCT/US2009/002536 patent/WO2009131702A2/en active Application Filing
- 2009-04-24 TW TW103126334A patent/TWI547287B/zh active
- 2009-04-24 MX MX2010011679A patent/MX2010011679A/es active IP Right Grant
- 2009-04-24 US US12/429,529 patent/US8273351B2/en active Active
- 2009-04-24 CN CN201410357602.2A patent/CN104479017A/zh active Pending
- 2009-04-24 KR KR1020177030420A patent/KR102072896B1/ko active IP Right Grant
- 2009-04-24 CA CA2722082A patent/CA2722082C/en active Active
- 2009-04-24 AU AU2009238605A patent/AU2009238605B2/en not_active Expired - Fee Related
- 2009-04-24 EP EP19210915.5A patent/EP3670538A1/en active Pending
- 2009-04-24 KR KR1020197025353A patent/KR20190104432A/ko not_active Application Discontinuation
- 2009-04-24 CA CA3131470A patent/CA3131470A1/en active Pending
- 2009-04-24 EP EP17195757.4A patent/EP3348573B1/en active Active
- 2009-04-24 SG SG10201804513WA patent/SG10201804513WA/en unknown
- 2009-04-24 JP JP2011506301A patent/JP6106854B2/ja active Active
- 2009-04-24 KR KR1020167016843A patent/KR101837329B1/ko active IP Right Grant
- 2009-04-24 NZ NZ589451A patent/NZ589451A/en unknown
- 2009-04-24 CN CN201710530059.5A patent/CN108467431A/zh active Pending
- 2009-04-24 TW TW098113830A patent/TWI453031B/zh active
- 2009-04-24 SG SG10202105499WA patent/SG10202105499WA/en unknown
- 2009-04-24 KR KR1020107026415A patent/KR101634719B1/ko active IP Right Grant
- 2009-04-24 BR BRPI0910622-7A patent/BRPI0910622A2/pt not_active Application Discontinuation
- 2009-04-24 ES ES09734929.4T patent/ES2650804T3/es active Active
- 2009-04-24 TW TW105116324A patent/TWI593423B/zh active
- 2009-04-24 SG SG2014004063A patent/SG196839A1/en unknown
- 2009-04-24 CN CN200980124409.1A patent/CN102149729B/zh active Active
- 2009-04-24 EP EP09734929.4A patent/EP2310415B8/en active Active
-
2010
- 2010-10-20 IL IL208846A patent/IL208846A/en active IP Right Grant
- 2010-11-03 ZA ZA2010/07873A patent/ZA201007873B/en unknown
-
2012
- 2012-02-07 HK HK12101148.5A patent/HK1160868A1/xx unknown
- 2012-08-13 US US13/584,221 patent/US20130045218A1/en not_active Abandoned
- 2012-09-14 US US13/617,498 patent/US8815246B2/en active Active
-
2014
- 2014-01-30 US US14/168,839 patent/US9260520B2/en active Active
-
2015
- 2015-02-16 JP JP2015027638A patent/JP5989159B2/ja active Active
- 2015-08-06 HK HK15107570.6A patent/HK1207089A1/xx unknown
- 2015-09-03 IL IL241091A patent/IL241091B/en active IP Right Grant
- 2015-12-22 US US14/979,165 patent/US20160222108A1/en not_active Abandoned
- 2015-12-29 US US14/982,649 patent/US20160222110A1/en not_active Abandoned
- 2015-12-29 US US14/982,521 patent/US20160222109A1/en not_active Abandoned
- 2015-12-30 US US14/984,075 patent/US20160222111A1/en not_active Abandoned
- 2015-12-30 US US14/984,162 patent/US20160222112A1/en not_active Abandoned
- 2015-12-31 US US14/985,614 patent/US20160194397A1/en not_active Abandoned
-
2016
- 2016-08-08 JP JP2016155218A patent/JP6499132B2/ja active Active
-
2019
- 2019-03-14 JP JP2019046955A patent/JP2019162105A/ja active Pending
-
2022
- 2022-05-02 JP JP2022075914A patent/JP2022115960A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011523351A5 (ja) | ||
JP2019162105A5 (ja) | ||
JP2011520898A5 (ja) | ||
JP2012524071A5 (ja) | ||
JP2018512138A5 (ja) | ||
RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
JP2010526028A5 (ja) | ||
JP2015535828A5 (ja) | ||
JP2008516970A5 (ja) | ||
RU2481356C2 (ru) | Моноклональные антитела против nkg2a | |
Chu et al. | Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody | |
WO2021055253A3 (en) | Anti-tnfr2 antibodies and methods of use | |
JP2020023523A5 (ja) | ||
FI2897981T3 (fi) | Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä | |
JP2017505622A5 (ja) | ||
JP2017079785A5 (ja) | ||
NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
JP2017522043A5 (ja) | ||
JP2016507523A5 (ja) | ||
RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
JP2011524858A5 (ja) | ||
JP2014509837A5 (ja) | ||
JP2017505125A5 (ja) | ||
JP2012531922A5 (ja) | Toll様受容体2へのヒト化抗体またはその抗原結合部位 |